Biomimetics (Aug 2018)

Biosafety of Mesoporous Silica Nanoparticles

  • Estelle Rascol,
  • Cédric Pisani,
  • Christophe Dorandeu,
  • Jeff L. Nyalosaso,
  • Clarence Charnay,
  • Morgane Daurat,
  • Afitz Da Silva,
  • Jean-Marie Devoisselle,
  • Jean-Charles Gaillard,
  • Jean Armengaud,
  • Odette Prat,
  • Marie Maynadier,
  • Magali Gary-Bobo,
  • Marcel Garcia,
  • Joël Chopineau,
  • Yannick Guari

DOI
https://doi.org/10.3390/biomimetics3030022
Journal volume & issue
Vol. 3, no. 3
p. 22

Abstract

Read online

Careful analysis of any new nanomedicine device or disposal should be undertaken to comprehensively characterize the new product before application, so that any unintended side effect is minimized. Because of the increasing number of nanotechnology-based drugs, we can anticipate that regulatory authorities might adapt the approval process for nanomedicine products due to safety concerns, e.g., request a more rigorous testing of the potential toxicity of nanoparticles (NPs). Currently, the use of mesoporous silica nanoparticles (MSN) as drug delivery systems is challenged by a lack of data on the toxicological profile of coated or non-coated MSN. In this context, we have carried out an extensive study documenting the influence of different functionalized MSN on the cellular internalization and in vivo behaviour. In this article, a synthesis of these works is reviewed and the perspectives are drawn. The use of magnetic MSN (Fe3O4@MSN) allows an efficient separation of coated NPs from cell cultures with a simple magnet, leading to results regarding corona formation without experimental bias. Our interest is focused on the mechanism of interaction with model membranes, the adsorption of proteins in biological fluids, the quantification of uptake, and the effect of such NPs on the transcriptomic profile of hepatic cells that are known to be readily concerned by NPs’ uptake in vivo, especially in the case of an intravenous injection.

Keywords